COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Monika Gawalko; Agnieszka Kaplon-Cieslicka; Mathias Hohl; Dobromir Dobrev; Dominik Linz

doi:10.1016/j.ijcha.2020.100631

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Monika Gawalko^*, Agnieszka Kaplon-Cieslicka, Mathias Hohl, Dobromir Dobrev, Dominik Linz

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Original language	English
Article number	100631
Number of pages	8
Journal	IJC Heart & Vasculature
Volume	30
DOIs	https://doi.org/10.1016/j.ijcha.2020.100631
Publication status	Published - Oct 2020

Keywords

ACE2
AMIODARONE
ARRHYTHMIAS
Anticoagulation
Arrhythmia
CRITICALLY-ILL PATIENTS
DISEASE
DYSFUNCTION
INFLAMMATION
Inflammasome
OBSTRUCTIVE RESPIRATORY EVENTS
OUTCOMES
PROMOTES
RECEPTOR
Remote monitoring
Thromboembolic risk
ACTIVATION

Access to Document

10.1016/j.ijcha.2020.100631Licence: CC BY-NC-ND

Cite this

@article{432e7dd943c34eaa8b5a0dd3fca4e2d1,

title = "COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications",

abstract = "Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).",

keywords = "ACE2, AMIODARONE, ARRHYTHMIAS, Anticoagulation, Arrhythmia, CRITICALLY-ILL PATIENTS, DISEASE, DYSFUNCTION, INFLAMMATION, Inflammasome, OBSTRUCTIVE RESPIRATORY EVENTS, OUTCOMES, PROMOTES, RECEPTOR, Remote monitoring, Thromboembolic risk, ACTIVATION",

author = "Monika Gawalko and Agnieszka Kaplon-Cieslicka and Mathias Hohl and Dobromir Dobrev and Dominik Linz",

year = "2020",

month = oct,

doi = "10.1016/j.ijcha.2020.100631",

language = "English",

volume = "30",

journal = "IJC Heart & Vasculature",

issn = "2352-9067",

publisher = "Elsevier",

}

TY - JOUR

T1 - COVID-19 associated atrial fibrillation

T2 - Incidence, putative mechanisms and potential clinical implications

AU - Gawalko, Monika

AU - Kaplon-Cieslicka, Agnieszka

AU - Hohl, Mathias

AU - Dobrev, Dobromir

AU - Linz, Dominik

PY - 2020/10

Y1 - 2020/10

N2 - Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

AB - Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

KW - ACE2

KW - AMIODARONE

KW - ARRHYTHMIAS

KW - Anticoagulation

KW - Arrhythmia

KW - CRITICALLY-ILL PATIENTS

KW - DISEASE

KW - DYSFUNCTION

KW - INFLAMMATION

KW - Inflammasome

KW - OBSTRUCTIVE RESPIRATORY EVENTS

KW - OUTCOMES

KW - PROMOTES

KW - RECEPTOR

KW - Remote monitoring

KW - Thromboembolic risk

KW - ACTIVATION

U2 - 10.1016/j.ijcha.2020.100631

DO - 10.1016/j.ijcha.2020.100631

M3 - (Systematic) Review article

C2 - 32904969

SN - 2352-9067

VL - 30

JO - IJC Heart & Vasculature

JF - IJC Heart & Vasculature

M1 - 100631

ER -